Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DATA CONTRIBUTED TO THE SCIENTIFIC AND CLINICAL RATIONALE FOR RASOLUTE 302, A PIVOTAL PHASE 3 TRIAL IN SECOND LINE TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC CANCER DATA CONTRIBUTED TO THE SCIENTIFIC AND CLINICAL RATIONALE FOR RASOLUTE 302, A PIVOTAL PHASE 3 TRIAL IN SECOND LINE TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC CANCER

REVOLUTION MEDICINES ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE OF PHASE 1/2 CLINICAL DATA ON DARAXONRASIB IN PANCREATIC CANCER

DARAXONRASIB DEMONSTRATED UNPRECEDENTED SURVIVAL BENEFIT IN PHASE 3 RASOLUTE 302 TRIAL IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER; DETAILED RESULTS WILL BE PRESENTED IN UPCOMING ASCO PLENARY PRESENTATION RASOLUTE 302 DATA PLANNED FOR SUBMISSION TO GLOBAL REGULATORY AUTHORITIES, INCLUDING THE U.S. FOOD AND DRUG ADMINISTRATION AACR 2026 PRESENTATIONS REINFORCE THE BREADTH AND STRENGTH OF COMPANY'S RAS(ON) PORTFOLIO, HIGHLIGHTING CONTINUED PROGRESS AND NOVEL APPROACHES TO RAS(ON) INHIBITION STRENGTHENED FINANCIAL POSITION WITH FINANCINGS TOTALING $2.2 BILLION IN GROSS PROCEEDS REVOLUTION MEDICINES TO HOLD WEBCAST TODAY AT 4:30 P.M. EASTERN TIME REDWOOD CITY, CALIF.

REVOLUTION MEDICINES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS

REDWOOD CITY, CALIF., APRIL 29, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 ON WEDNESDAY, MAY 6, 2026, AFTER MARKET CLOSE.

REVOLUTION MEDICINES TO REPORT FINANCIAL RESULTS FOR FIRST QUARTER 2026 AFTER MARKET CLOSE ON MAY 6, 2026

REDWOOD CITY, CALIF., APRIL 21, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED UPDATED CLINICAL DATA FROM TWO PHASE 1/2 TRIALS OF DARAXONRASIB, AN ORAL RAS(ON) MULTI-SELECTIVE INHIBITOR, IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC). DATA FROM THE DARAXONRASIB COMBINATION COHORT WILL BE PRESENTED IN A LATE-BREAKING MINI-SYMPOSIUM, AND DATA FROM THE MONOTHERAPY COHORT WILL BE PRESENTED IN A POSTER SESSION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING ON APRIL 21, 2026.

REVOLUTION MEDICINES TO PRESENT UPDATED PHASE 1/2 CLINICAL DATA FOR DARAXONRASIB IN FIRST LINE METASTATIC PANCREATIC CANCER ACROSS MONOTHERAPY AND COMBINATION COHORTS AT THE 2026 AACR ANNUAL MEETING

DATA HIGHLIGHT RM-055'S ABILITY TO OVERCOME RESISTANCE AND PROVIDE DEEP, DURABLE ANTITUMOR ACTIVITY ACROSS PRECLINICAL MODELS OF PANCREATIC DUCTAL ADENOCARCINOMA, NON-SMALL CELL LUNG CANCER AND COLORECTAL CANCER DATA HIGHLIGHT RM-055'S ABILITY TO OVERCOME RESISTANCE AND PROVIDE DEEP, DURABLE ANTITUMOR ACTIVITY ACROSS PRECLINICAL MODELS OF PANCREATIC DUCTAL ADENOCARCINOMA, NON-SMALL CELL LUNG CANCER AND COLORECTAL CANCER

REVOLUTION MEDICINES TO PRESENT PRECLINICAL DATA ON INNOVATIVE MUTANT-TARGETED CATALYTIC RAS(ON) INHIBITOR AT THE 2026 AACR ANNUAL MEETING

REDWOOD CITY, CALIF., APRIL 21, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT DETAILED RESULTS FROM THE GLOBAL, RANDOMIZED PHASE 3 RASOLUTE 302 CLINICAL TRIAL EVALUATING DARAXONRASIB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) WILL BE PRESENTED IN A PLENARY SESSION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TAKING PLACE MAY 29  JUNE 2, 2026 IN CHICAGO.

REVOLUTION MEDICINES TO PRESENT PIVOTAL PHASE 3 RASOLUTE 302 CLINICAL TRIAL RESULTS FOR DARAXONRASIB IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER DURING A PLENARY SESSION AT THE 2026 ASCO ANNUAL MEETING

REDWOOD CITY, CALIF., APRIL 19, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED UPDATED PHASE 1 (RMC-9805-001) CLINICAL DATA FOR ZOLDONRASIB, AN ORAL RAS(ON) G12D-SELECTIVE INHIBITOR, IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12D NON-SMALL CELL LUNG CANCER (NSCLC). RESULTS WERE HIGHLIGHTED IN THE OFFICIAL PRESS PROGRAM AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING AND WILL BE FEATURED IN A PLENARY ORAL PRESENTATION TODAY, APRIL 19, 2026, AT 1:30 P.M. PDT.

REVOLUTION MEDICINES TO PRESENT UPDATED PHASE 1 CLINICAL DATA FOR ZOLDONRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12D NON-SMALL CELL LUNG CANCER AT THE 2026 AACR ANNUAL MEETING

REDWOOD CITY, CALIF., APRIL 17, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THE CLOSING OF ITS CONCURRENT UPSIZED PUBLIC OFFERINGS OF 12,147,887 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $142.00 PER SHARE AND $500.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.50% CONVERTIBLE SENIOR NOTES DUE 2033 (THE NOTES). THE SHARES OF COMMON STOCK ISSUED AND SOLD IN THE COMMON STOCK OFFERING INCLUDE 1,584,506 SHARES ISSUED UPON EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS FROM THE OFFERINGS, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY REVOLUTION MEDICINES, WERE APPROXIMATELY $2,225.0 MILLION.

REVOLUTION MEDICINES ANNOUNCES CLOSING OF CONCURRENT UPSIZED PUBLIC OFFERINGS WITH AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $2.2 BILLION, INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

REDWOOD CITY, CALIF., APRIL 15, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THE PRICING OF ITS CONCURRENT PUBLIC OFFERINGS OF 10,563,381 SHARES OF COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $142.00 PER SHARE, FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $1.5 BILLION, AND $500.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.50% CONVERTIBLE SENIOR NOTES DUE 2033 (THE NOTES). THE OFFERING SIZE OF THE COMMON STOCK OFFERING WAS INCREASED FROM THE PREVIOUSLY ANNOUNCED OFFERING SIZE OF $750.0 MILLION AND THE OFFERING SIZE OF THE NOTE OFFERING WAS INCREASED FROM THE PREVIOUSLY ANNOUNCED OFFERING SIZE OF $250.0 MILLION. THE ISSUANCE AND SALE OF THE COMMON STOCK AND THE NOTES ARE SCHEDULED TO SETTLE ON APRIL 16, 2026 AND APRIL 17, 2026, RESPECTIVELY, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. REVOLUTION MEDICINES ALSO GRANTED THE UNDERWRITERS OF THE COMMON STOCK OFFERING A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,584,506 SHARES OF COMMON STOCK. THE COMPLETION OF THE COMMON STOCK OFFERING WILL NOT BE CONTINGENT ON THE COMPLETION OF THE NOTE OFFERING, AND THE COMPLETION OF THE NOTE OFFERING WILL NOT BE CONTINGENT ON THE COMPLETION OF THE COMMON STOCK OFFERING.

REVOLUTION MEDICINES, INC. PRICES $2.0 BILLION IN CONCURRENT UPSIZED OFFERINGS OF COMMON STOCK AND CONVERTIBLE SENIOR NOTES

REDWOOD CITY, CALIF., APRIL 13, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED ITS INTENTION TO OFFER, SUBJECT TO MARKET AND OTHER CONDITIONS, $750 MILLION OF COMMON STOCK AND $250 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2033 (THE NOTES) IN SEPARATE PUBLIC OFFERINGS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. REVOLUTION MEDICINES ALSO EXPECTS TO GRANT THE UNDERWRITERS OF THE COMMON STOCK OFFERING A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $112.5 MILLION OF COMMON STOCK, AND EXPECTS TO GRANT THE UNDERWRITERS OF THE NOTE OFFERING A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $37.5 MILLION PRINCIPAL AMOUNT OF NOTES SOLELY TO COVER OVER-ALLOTMENTS. THE COMPLETION OF THE COMMON STOCK OFFERING WILL NOT BE CONTINGENT ON THE COMPLETION OF THE NOTE OFFERING, AND THE COMPLETION OF THE NOTE OFFERING WILL NOT BE CONTINGENT ON THE COMPLETION OF THE COMMON STOCK OFFERING.

REVOLUTION MEDICINES, INC. ANNOUNCES PROPOSED OFFERINGS OF COMMON STOCK AND CONVERTIBLE SENIOR NOTES

REDWOOD CITY, CALIF., MARCH 17, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ:RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT NINE ORAL AND POSTER PRESENTATIONS HIGHLIGHTING ADVANCES ACROSS ITS RAS(ON) INHIBITOR PIPELINE WILL BE FEATURED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, TAKING PLACE APRIL 1722, 2026 IN SAN DIEGO.

REVOLUTION MEDICINES TO SHOWCASE PROGRESS ACROSS RAS(ON) TARGETED ONCOLOGY PIPELINE WITH MULTIPLE PRESENTATIONS AT THE 2026 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

Revolution Medicines, Inc.

RVMD

Price

Financial Reports

No items found.

Press Releases

Revolution Medicines, Inc.

RVMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RVMD